TYK Medicines Secures Exclusive Distribution of TY‑9591 in Mainland China
China-based TYK Medicines, Inc. (HKG: 2410) announced on August 26, 2025, that it has entered...
August 2025
Fosun Pharma Reports 4.6% Revenue Decline in 2025 H1 – Innovative Drugs Drive Growth
China‑based Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) released its 2025 first‑half...
C‑MER Announces Acquisition of Hong Kong Endoscopy Centre
C‑MER Eye Care Medical Group Limited (HKG: 3309) on 26 August, 2025 disclosed plans to acquire a...
Junshi Biosciences Reports 49% Revenue Growth in H1 2025
Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) released its interim financials for the...
Innogen Commences Phase II Trial of Efsubaglutide Alfa for Obesity in Australia
Shanghai Innogen Pharmaceutical Technology Co., Ltd. (HKG: 2591) announced on 26 August, 2025 that the first...
Humanwell Secures NMPA Approval for Remimazolam ICU Sedation
China‑based Humanwell Healthcare (Group) Co., Ltd. (SHA: 600079) announced that the National Medical Products Administration...
Eisai & Biogen Launch Lecanemab in Austria & Germany – First Cause‑Based Alzheimer’s Therapy
Japan-based Eisai (TYO: 4523) and US-based Biogen (NASDAQ: BIIB) have officially launched Lecanemab (LEQEMBI)—the first...
BioArctic & Novartis Announce BrainTransporter‑Enabled Neurodegeneration Collaboration – Up to $772 M Potential Pay‑Out
Swedish biopharma BioArctic AB (publ) (STO: BIOA-B) has entered into an option, collaboration, and license...
Anke Biotech Secures Long‑Acting FSH‑CTP Approval in China
Shanghai Bao Pharmaceuticals Co., Ltd. has received official marketing authorization from China’s National Medical Products Administration (NMPA)...
Cloudbreak Pharma Profit Highlights Turnaround in Ophthalmic Biotech
Clinical-stage ophthalmic biotech Cloudbreak Pharma Inc. (HKG: 2592) announced a positive profit alert for the...
Minova Rongzhi Funding Surge: Series B Backed by IDG Capital
Nanjing‑based Minova Pharmaceuticals Co., Ltd. closed a Series B financing round worth hundreds of millions of...
Walvax Biotechnology Reports 19.5% Revenue Drop, Faces HPV Vaccine Impairment
China‑based Walvax Biotechnology Co., Ltd. (SHE: 300142) disclosed its financial results for the first half...
AbbVie Acquires Bretisilocin from Gilgamesh in $1.2B Deal for MDD Treatment
American pharmaceutical giant AbbVie (NYSE: ABBV) has finalized a definitive agreement to acquire bretisilocin, an...
Hengrui Pharmaceuticals Secures NMPA Approval for HRS‑2162 and HRS‑6093 Clinical Trials
China‑based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) announced that its two investigational...
Yichang Humanwell Partners with DP Technology to Leverage Hermite Platform for Drug Discovery
China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) has announced a strategic partnership with DP...
Wusheng Erlunbao: Sinopharm’s First‑of‑Its‑Kind Hexavalent Rotavirus Vaccine Receives NMPA Approval
The Wuhan Institute of Biological Products Co., Ltd., a subsidiary of Sinopharm Group Co., Ltd....
Lepu Medical Secures NMPA Approval for Innovative Sodium Hyaluronate Dermal Filler
China-based Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003) announced today that its self‑developed Class III...
InxMed Secures HK$100 M Private Placement from TruMed Health
On August 26, 2025, Hong Kong‑listed China-based InxMed (Nanjing) Co., Ltd (HKG: 2509) announced that it has...
Chengdu Ucello’s UC101 CAR‑T Gains NMPA Approval
China‑based Chengdu Ucello Biotechnology Co., Ltd. announced that its Investigational New Drug (IND) application for...
Henlius, Serplulimab and Abbott Drive Robust 2025 Financials
Shanghai Henlius Biotech, Inc. (HKG: 2696) released its 2025 first‑half financials, reporting a 2.7 % year‑on‑year...